{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:11:38Z","timestamp":1777587098609,"version":"3.51.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Anticoagulation can prevent stroke and prolong lives in patients with atrial fibrillation (AF). However, anticoagulated patients with AF remain at risk of death. The aim of this study was to investigate the causes of death and factors associated with all-cause and cardiovascular death in the XANTUS population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Causes of death occurring within a year after rivaroxaban initiation in patients in the XANTUS programme studies were adjudicated by a central adjudication committee and classified following international guidance. Baseline characteristics associated with all-cause or cardiovascular death were identified. Of 11 040 patients, 187 (1.7%) died. Almost half of these deaths were due to cardiovascular causes other than bleeding (n = 82, 43.9%), particularly heart failure (n = 38, 20.3%) and sudden or unwitnessed death (n = 24, 12.8%). Fatal stroke (n = 8, 4.3%), which was classified as a type of cardiovascular death, and fatal bleeding (n = 17, 9.1%) were less common causes of death. Independent factors associated with all-cause or cardiovascular death included age, AF type, body mass index, left ventricular ejection fraction, hospitalization at baseline, rivaroxaban dose, and anaemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The overall risk of death due to stroke or bleeding was low in XANTUS. Anticoagulated patients with AF remain at risk of death due to heart failure and sudden death. Potential interventions to reduce cardiovascular deaths in anticoagulated patients with AF require further investigation, e.g. early rhythm control therapy and AF ablation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>NCT01606995, NCT01750788, NCT01800006<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euae183","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:58:00Z","timestamp":1719413880000},"source":"Crossref","is-referenced-by-count":8,"title":["Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Heart and Vascular Center UKE Hamburg , Martinistra\u00dfe 52, Geb\u00e4ude Ost 70, 20246 Hamburg , Germany"},{"name":"German Center for Cardiovascular Research (DZHK), partner site Hamburg\/Kiel\/L\u00fcbeck , Hamburg , Germany"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham , Birmingham , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-7892","authenticated-orcid":false,"given":"Sylvia","family":"Haas","sequence":"additional","affiliation":[{"name":"Formerly Technical University Munich , Munich , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-1236","authenticated-orcid":false,"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke Centre, Paris-Diderot-Sorbonne University , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G G","family":"Turpie","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6626-7141","authenticated-orcid":false,"given":"Miriam","family":"Bach","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lambelet","sequence":"additional","affiliation":[{"name":"Chrestos Concept GmbH & Co KG , Essen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Hess","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-2871","authenticated-orcid":false,"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiovascular and Cell Sciences Research Institute, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"2024073112174851500_euae183-B1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"2024073112174851500_euae183-B2","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"},{"key":"2024073112174851500_euae183-B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2024073112174851500_euae183-B4","first-page":"e15","article-title":"New versus traditional approaches to oral anticoagulation in patients with atrial fibrillation","volume":"127","author":"Reiffel","year":"2014","journal-title":"Am J Med"},{"key":"2024073112174851500_euae183-B5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024073112174851500_euae183-B6","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","article-title":"Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study","volume":"128","author":"Marijon","year":"2013","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B7","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF","volume":"5","author":"Pokorney","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024073112174851500_euae183-B8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1573403X10666140902143020","article-title":"How does chronic atrial fibrillation influence mortality in the modern treatment era?","volume":"11","author":"Sankaranarayanan","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"2024073112174851500_euae183-B9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/VHRM.S63298","article-title":"XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation","volume":"10","author":"Camm","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"2024073112174851500_euae183-B10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jacc.2018.04.058","article-title":"Global prospective safety analysis of rivaroxaban","volume":"72","author":"Kirchhof","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024073112174851500_euae183-B11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"2024073112174851500_euae183-B12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/joa3.12073","article-title":"XANAP: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia","volume":"34","author":"Kim","year":"2018","journal-title":"J Arrhythm"},{"key":"2024073112174851500_euae183-B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ehj.2018.09.002","article-title":"XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America","volume":"70","author":"Martinez","year":"2018","journal-title":"Egypt Heart J"},{"key":"2024073112174851500_euae183-B14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1214\/aos\/1176344198","article-title":"Nonparametric estimation of partial transition probabilities in multiple decrement models","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann Statist"},{"key":"2024073112174851500_euae183-B15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2024073112174851500_euae183-B16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/clc.22565","article-title":"Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy","volume":"39","author":"Coleman","year":"2016","journal-title":"Clin Cardiol"},{"key":"2024073112174851500_euae183-B17","doi-asserted-by":"crossref","first-page":"e0191592","DOI":"10.1371\/journal.pone.0191592","article-title":"Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation","volume":"13","author":"Bassand","year":"2018","journal-title":"PLoS One"},{"key":"2024073112174851500_euae183-B18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.amjcard.2017.02.050","article-title":"Effect of atrial fibrillation on mortality, stroke risk, and quality-of-life scores in patients with heart failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF])","volume":"119","author":"Cherian","year":"2017","journal-title":"Am J Cardiol"},{"key":"2024073112174851500_euae183-B19","doi-asserted-by":"crossref","first-page":"e026410","DOI":"10.1161\/JAHA.122.026410","article-title":"Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II\/III of the GLORIA-AF registry","volume":"11","author":"Ding","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024073112174851500_euae183-B20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2018.05.034","article-title":"Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry","volume":"271","author":"Boriani","year":"2018","journal-title":"Int J Cardiol"},{"key":"2024073112174851500_euae183-B21","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00380-018-1194-5","article-title":"Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry","volume":"33","author":"An","year":"2018","journal-title":"Heart Vessels"},{"key":"2024073112174851500_euae183-B22","doi-asserted-by":"crossref","first-page":"e000290","DOI":"10.1136\/openhrt-2015-000290","article-title":"Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study","volume":"2","author":"Fauchier","year":"2015","journal-title":"Open Heart"},{"key":"2024073112174851500_euae183-B23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1378\/chest.15-1622","article-title":"Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project","volume":"149","author":"Fauchier","year":"2016","journal-title":"Chest"},{"key":"2024073112174851500_euae183-B24","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","author":"Banerjee","year":"2013","journal-title":"Int J Cardiol"},{"key":"2024073112174851500_euae183-B25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024073112174851500_euae183-B26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.121.056323","article-title":"Early rhythm control therapy in patients with atrial fibrillation and heart failure","volume":"144","author":"Rillig","year":"2021","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter ablation in end-stage heart failure with atrial fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N Engl J Med"},{"key":"2024073112174851500_euae183-B28","doi-asserted-by":"crossref","first-page":"e003735","DOI":"10.1161\/JAHA.116.003735","article-title":"Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Eisen","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024073112174851500_euae183-B29","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"G\u00f3mez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024073112174851500_euae183-B30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024073112174851500_euae183-B31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jchf.2016.07.012","article-title":"Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis","volume":"4","author":"Savarese","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2024073112174851500_euae183-B33","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/joa3.12652","article-title":"2021 focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation","volume":"37","author":"Chao","year":"2021","journal-title":"J Arrhythm"},{"key":"2024073112174851500_euae183-B34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B35","doi-asserted-by":"crossref","first-page":"euae070","DOI":"10.1093\/europace\/euae070","article-title":"Longer and better lives for patients with atrial fibrillation: the 9th AFNET\/EHRA consensus conference","volume":"26","author":"Linz","year":"2024","journal-title":"Europace"},{"key":"2024073112174851500_euae183-B36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"2024073112174851500_euae183-B37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2024073112174851500_euae183-B38","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"ACTIVE Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2024073112174851500_euae183-B39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/ijms.11924","article-title":"Anemia as an independent predictor of adverse cardiac outcomes in patients with atrial fibrillation","volume":"12","author":"Lee","year":"2015","journal-title":"Int J Med Sci"},{"key":"2024073112174851500_euae183-B40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ahj.2009.03.009","article-title":"Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation","volume":"157","author":"Sharma","year":"2009","journal-title":"Am Heart J"},{"key":"2024073112174851500_euae183-B41","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2024073112174851500_euae183-B42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial","volume":"24","author":"Metzner","year":"2022","journal-title":"Europace"},{"key":"2024073112174851500_euae183-B43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.122.060274","article-title":"Early rhythm control in patients with atrial fibrillation and high comorbidity burden","volume":"146","author":"Rillig","year":"2022","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B45","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCULATIONAHA.118.035774","article-title":"Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery","volume":"139","author":"Aragam","year":"2019","journal-title":"Circulation"},{"key":"2024073112174851500_euae183-B47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1540-8167.2001.00680.x","article-title":"Brugada syndrome and supraventricular tachyarrhythmias: a novel association?","volume":"12","author":"Eckardt","year":"2001","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024073112174851500_euae183-B48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1540-8167.2008.01339.x","article-title":"Atrial arrhythmias in long-QT syndrome under daily life conditions: a nested case control study","volume":"20","author":"Zellerhoff","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2024073112174851500_euae183-B49","doi-asserted-by":"publisher","first-page":"qcad077","DOI":"10.1093\/ehjqcco\/qcad077","article-title":"Clinical outcomes in hospitalized patients with cancer and new versus preexistent atrial fibrillation","author":"Kosmidou","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2024073112174851500_euae183-B50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12916-024-03308-z","article-title":"Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors","volume":"22","author":"Park","year":"2024","journal-title":"BMC Med"},{"key":"2024073112174851500_euae183-B51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jjcc.2018.12.003","article-title":"Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: a SAKURA AF Registry substudy","volume":"73","author":"Kuronuma","year":"2019","journal-title":"J Cardiol"},{"key":"2024073112174851500_euae183-B52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjcvp\/pvy041","article-title":"Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study","volume":"5","author":"Amarenco","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024073112174851500_euae183-B53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/clc.23764","article-title":"Associations of anemia with death and major bleeding in patients with atrial fibrillation: a report from the Chinese Atrial Fibrillation Registry Study","volume":"45","author":"Zhang","year":"2022","journal-title":"Clin Cardiol"},{"key":"2024073112174851500_euae183-B54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euaa279","article-title":"Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET\/EHRA Consensus Conference","volume":"23","author":"Fabritz","year":"2021","journal-title":"Europace"},{"key":"2024073112174851500_euae183-B55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024073112174851500_euae183-B56","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"2024073112174851500_euae183-B57","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/europace\/euac214","article-title":"Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry","volume":"25","author":"Ding","year":"2023","journal-title":"Europace"},{"key":"2024073112174851500_euae183-B58","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/europace\/euac082","article-title":"Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial","volume":"24","author":"Patel","year":"2022","journal-title":"Europace"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euae183\/58361436\/euae183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/7\/euae183\/58589443\/euae183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/7\/euae183\/58589443\/euae183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:59:38Z","timestamp":1722477578000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euae183\/7701365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euae183","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,29]]},"article-number":"euae183"}}